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Abstract 
Background: Cerebral malaria (CM) is debilitating and sometimes fatal. Disease severity has been associated with 
poor treatment access, therapeutic complexity and drug resistance and, thus, alternative therapies are increasingly 
necessary. In this study, the effect of the administration of Agaricus blazei, a mushroom of Brazilian origin in a model of 
CM caused by Plasmodium berghei, strain ANKA, was investigated in mice.
Methods: C57BL/6 mice were pre-treated with aqueous extract or fractions of A. blazei, or chloroquine, infected 
with P. berghei ANKA and then followed by daily administration of A. blazei or chloroquine. Parasitaemia, body weight, 
survival and clinical signs of the disease were evaluated periodically. The concentration of pro-and anti-inflammatory 
cytokines, histopathology and in vitro analyses were performed.
Results: Mice treated with A. blazei aqueous extract or fraction C, that shows antioxidant activity, displayed lower 
parasitaemia, increased survival, reduced weight loss and protection against the development of CM. The admin-
istration of A. blazei resulted in reduced levels of TNF, IL-1β and IL-6 production when compared to untreated P. 
berghei-infected mice. Agaricus blazei (aqueous extract or fraction C) treated infected mice displayed reduction of 
brain lesions. Although chloroquine treatment reduced parasitaemia, there was increased production of proinflam-
matory cytokines and damage in the CNS not observed with A. blazei treatment. Moreover, the in vitro pretreatment 
of infected erythrocytes followed by in vivo infection resulted in lower parasitaemia, increased survival, and little 
evidence of clinical signs of disease.
Conclusions: This study strongly suggests that the administration of A. blazei (aqueous extract or fraction C) was 
effective in improving the consequences of CM in mice and may provide novel therapeutic strategies.
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Background
There is a rich history of the use of natural products in 
the treatment of parasitic diseases, including malaria. 
Mushrooms have been used for nutritional and medici-
nal purposes since ancient times [1]. The mushroom 
Agaricus blazei is of Brazilian origin and has been used 
as a functional food and a popular medicine [2]. Many 
laboratories have investigated the effect of A. blazei bio-
active components as an antioxidant [3–5] and as immu-
nomodulatory agents [6, 7]. There is increased interest in 
these compounds in various disease states, such as can-
cer [7–11], allergy [12, 13], inflammatory diseases [13, 
14], viral and bacterial infections [6, 7, 15], diabetes [16, 
17] and cholesterol biosynthesis [16]. Furthermore, there 
has been great interest in the use of this mushroom in the 
treatment of leishmaniasis [18–20]. The use of this mush-
room in the treatment of malaria has not been evaluated.
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Malaria, caused by Plasmodium species remains an 
important cause of morbidity and mortality especially in 
Africa, parts of Asia and Latin America. Malaria accounts 
for millions of deaths and many more millions are at risk. 
Infections caused by Plasmodium falciparum are often 
the most severe [21]. The most debilitating phenotype of 
severe malaria is a neurological syndrome known as cer-
ebral malaria (CM) [22–24], which predominantly affects 
children in sub-Saharan Africa. This disease has a mor-
tality rate around 20  % and is accompanied by seizures 
and neurocognitive dysfunction [21, 25]. The treatment 
of CM in endemic areas is complicated due to lack of 
access and cost of drugs and the development of resist-
ance [23, 26–29]. Additionally, as noted successful anti-
malarial therapy is effective in eliminating the parasite 
from the bloodstream, but does not prevent the develop-
ment of neuronal damage [26, 28, 29].
Agaricus blazei, or some of its fractions, stimulates 
the immune response, including TNF and IL-8 produc-
tion by macrophages [30] and stimulates IL-1β and IL-6 
in human monocytes and endothelial cells [6]. Studies in 
healthy individuals fed A. blazei demonstrated significant 
reduction in cytokine levels including TNF, IL-1β, IL-2, 
IL-6, and IL-17 in human blood [31]. Blood cells obtained 
from patients, with inflammatory bowel disease treated 
with A. blazei had reduced levels of IL-1β, IL-6, IL-8, 
MCP-1 and G-CSF when stimulated with LPS in  vitro 
[14]. Johnson et al. [31] observed in human healthy vol-
unteers, after oral A. blazei, elevated levels of, IFN-γ, 
IL-2, IL-4, IL-10, IL-12 and IL-17 in blood/serum.
An aqueous extract of A. blazei reduced the parasite 
infectivity, load and viability [18] in murine macrophages 
infected with different species of Leishmania. Addition-
ally, Leishmania amazonensis-infected mice treated with 
aqueous extract of A. blazei displayed a reduction of the 
lesions size, a reduction of parasite load in the spleen 
and lymph nodes, an elevation of IFN-γ and decreased 
IL-4 and IL-10 in the spleen and in lymphoid nodules, 
respectively [19]. A. blazei has also been used in the 
prophylaxis and treatment of Leishmania chagasi infec-
tion [20].
Herein, there is evidence that A. blazei has antioxidant 
activity and that A. blazei extract or a purified fraction 
inhibited the production of pro-inflammatory cytokines 
in the brain (TNF, IL-1β and IL-6) and spleen (IFN-γ, IL-6 
and IL-17) during Plasmodium berghei (strain ANKA) 
infection preventing the development of severe disease. 
Treatment with chloroquine resulted in an increased 
production of most pro-inflammatory cytokines analyzed 
in the brain when compared to untreated-infected and A. 
blazei-treated infected mice. We also demonstrated that 
A. blazei and chloroquine administration decreased par-
asitaemia, increased survival, but A. blazei demonstrated 
greater protection against brain damage when compared 
with chloroquine.
Methods
Preparation of the aqueous extract and fractions purified 
of the mushroom Agaricus blazei
Agaricus blazei aqueous extract was prepared by mix-
ing 5  g of the mushroom powder form with 50  mL of 
milli-Q water at a concentration of 1.5  % (weight/vol-
ume) for a 2 h incubation at room temperature, followed 
by centrifugation at 7,800×g (Thermo Scientific Heraus 
Multifuge X1R) at 4 °C for 30 min. The supernatant was 
obtained (crude aqueous extract) and subjected to lyo-
philization (Lyophilizer LIOTOP, K105) at a temperature 
of −101 °C and a pressure of 23 mmHg for 48 h. At the 
end of this process a product was obtained (crude lyophi-
lized extract). The aqueous extract underwent centrifuga-
tion at 2,000×g for 45 min at 4 °C using different columns 
(to give three fractions with different molecular weights). 
The samples were subjected to the same process lyophi-
lizing as above and then it were stored at −20  °C, until 
use. This procedure has been patented at CT&T/UFMG.
Chemical profile
For the determination of all chemical compounds present 
in A. blazei, the lyophilized samples were resuspended 
in advance at a concentration of 1 mg/mL. All tests were 
performed in triplicate.
Protein determination by the Lowry method
Protein determinations of A. blazei extracts and fractions 
were performed with aliquots of 30  μL of each sample 
by adding 170  μL of Milli-Q water and 2.1  mL of biu-
ret (Synth, Diadema, São Paulo, Brazil). After 10 min in 
the dark, 200 μL of a solution of Folin–Ciocalteau (1:2) 
(Sigma-Aldrich, St. Louis, MO, USA) was added, samples 
were then homogenized by vortex (Cyclo mixer—Clay 
Adams) and left to stand in the dark for 1 h. Absorbance 
was then measured at 750  nm in a spectrophotometer 
(Shimaduzu, UV-160A). Milli-Q water was used as a neg-
ative control following the same pattern of samples con-
taining biuret solution and Folin–Ciocalteau solution. A 
calibration curve was constructed with different concen-
trations of bovine serum albumin (BSA) (Sigma-Aldrich, 
St. Louis, MO, USA) for comparison.
Determination of phenolic compounds
The determination of phenol compounds in A. blazei 
mushroom Fractions and extract was performed using 
80  μL aliquot of each sample. For analysis we added 
320  μL of methanol (Sigma-Aldrich, St. Louis, MO, 
USA), 250  μL of Folin–Ciocalteau (Sigma-Aldrich, St. 
Louis, MO, USA), 3  mL of Milli-Q water and 1  ml of 
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sodium carbonate 15  % (w/v) (Synth, Diadema, São 
Paulo, Brazil). Homogenization was performed in shaker 
(Cyclo mixer—Clay Adams), the samples were kept in the 
dark for 1 h. Afterwards, absorbance was determined at 
750 nm in a spectrophotometer (Shimaduzu, UV-160A). 
As a negative control, enzymatic reaction was used, 
80 μL of methanol following the same pattern of samples 
containing Folin–Ciocalteau reagent (Sigma-Aldrich, St. 
Louis, MO, USA), Milli-Q water and sodium carbonate 
15 % (w/v) (Synth, Diadema, São Paulo, Brazil). Samples 
were then compared to a calibration curve of different 
concentrations of gallic acid (Riedel-de Haën) 0.5  mg/
mL.
Determination of flavonoids
To an aliquot of 200 μL we added 800 μL of ethanol, to 
samples and then its was diluted with 150 μL of sodium 
carbonate 10.6  %, 300 μL of aluminum chloride in 2  % 
methanol (all reagents from Synth, Diadema, São Paulo, 
Brazil), 1  mL of sodium hydroxide 1  M (Merck KGaA, 
Darmstadt, Germany) and 1 mL of Milli-Q water. After 
5 min of incubation, the absorbance was read at 410 nm 
in a spectrophotometer (Shimaduzu, UV-160A). As a 
negative control, enzymatic reaction was used, 1  mL of 
Milli-Q water, 800  μL of ethanol (Synth, Diadema, São 
Paulo, Brazil), sodium carbonate 10.6 %, aluminum chlo-
ride 2 % and 1 mL of sodium hydroxide (Sigma-Aldrich, 
St. Louis, MO, USA) for comparison. Subsequently, the 
percentage of flavonoids was calculated in the total sam-
ple weight.
Determination of carbohydrates
Samples were diluted (50×), and 200 μL aliquots stored 
until further use. 200 μL of phenol solution (5 %) (Merck 
KGaA, Darmstadt, Germany) were added to the sam-
ple, followed by 1 ml of sulfuric acid (Sigma-Aldrich, St. 
Louis, MO, USA). The homogenization was performed in 
shaker (Cyclo mixer—Clay Adams) and after 15 min, the 
absorbance was read at 480 nm using a UV–VIS spectro-
photometer (Shimaduzu, UV-160A). As a negative con-
trol we used 200 μL of reaction solution, Milli-Q water, 
200 μL of phenol reagent and 1  ml of sulfuric acid (all 
reagents from Merck KGaA, Darmstadt, Germany). A 
calibration curve with standard solutions of glucose was 
constructed for comparison and calculation of the per-
centage in the total sample weight.
Test of antioxidant activity
Antioxidant activity was determined by the method of 
DPPH (2,2-diphenyl-1-picryl-hydrazyl) (Sigma-Aldrich, 
St. Louis, MO, USA) proposed by Brand-Williams 
et al. [32]. Briefly, to 5 µL of sample we added 195 µL of 
DPPH solution (60  µM). The absorbance reading was 
performed in a spectrophotometer at 515  nm (Varios-
kan Flash, Thermo Scientific) until its stabilization. The 
maximum antioxidant activity was calculated by con-
verting the absorbance percentage in antioxidant activ-
ity (AA maximum) using the formula: AA maximum 
(%)  =  100  −  {[(Abs sample  −  Abs blank)  ×  100]/Abs 
control}. The negative control was prepared with 5  µL 
of methanol solution (50  %) and 195  µL of DPPH. The 
decrease in absorbance represents stabilization of this 
free radical.
Polyacrylamide gel electrophoresis
Samples of A. blazei extract or fractions were subjected 
to PAGE in the presence of SDS [33]. Briefly, electro-
phoretic run was performed in a vertical electrophore-
sis containing running buffer (0.025  M Tris–HCl, pH 
8.3, 0.1  % SDS) under constant voltage (100  V) for 3  h 
and 30  min. After migration, the protein in the gel was 
stained according to the silver method staining and the 
gel washed with Milli-Q water five times for 5 min each 
wash. After 2 h in the pre-fixative A (solution 50 % meth-
anol and 7.5 % acetic acid), there was an additional of 2 h 
incubation in pre-fixative B (solution 5 % methanol and 
7.5 % acid acetic acid).
Administration of extracts or fractions of Agaricus blazei
Wild-type (WT) C57BL/6 females (8–10  weeks old) 
mice were obtained from the Animal Care Facilities of 
Federal University of Minas Gerais, Belo Horizonte, Bra-
zil. C57BL/6 mice females (n =  5  mice/group) received 
by gavage (3  days before infection) 250  μL daily of 
crude extract or Fractions of A. blazei or chloroquine—
hydroxychloroquine sulfate (Aspen Pharma, Johannes-
burg, South Africa, antimalarial drug used as control in 
the experiments). Doses used were as follows: aqueous 
extract: 10 and 100  mg/kg of body weight; lyophilized 
extract: 80 and 800 mg/kg of weight; fraction A: 10 mg/
kg of weight; fraction B: 10, 80 and 800 mg/kg of weight; 
fraction C: 100 and 800  mg/kg of weight; chloroquine: 
30  mg/kg of weight. Dosages were based on the weight 
of 25 g/animal. Extracts and fractions were diluted and/
or suspended in Milli-Q water in order to keep the con-
centration and dose similar. After pretreatment with 
crude extract or fractions of A. blazei or chloroquine for 
3 days, mice were infected with P. berghei (strain ANKA), 
followed by continuous administration of A. blazei or 
chloroquine until 7  dpi. Experiments were performed 
on day 5 post-infection (dpi) when P. berghei-infected 
mice develop brain inflammation without motor impair-
ment [34, 35]. This study was carried out in strict accord-
ance with the Brazilian Guidelines on animal work and 
the Guide for the Care and Use of Laboratory Animals 
of the National Institutes of Health. The animal ethics 
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committee of the Universidade Federal de Minas Gerais 
CETEA/UFMG approved all experiments and proce-
dures including euthanasia, fluid and organ removal (Per-
mit Number: 262/11).
Parasitology and experimental infection
Blood stages of P. berghei constitutively expressing green 
fluorescent protein (P. berghei ANKA-GFP) (15cy1 clone) 
[24], kindly provided by Dr. Claudio Marinho (Univer-
sity of São Paulo), were stored in liquid nitrogen. Mice 
were infected intraperitoneally (i.p.) with 105 P. berghei-
infected red blood cells suspended in 0.2  mL PBS. The 
percentage of parasitaemia was quantified by GFP fre-
quency in whole blood using flow cytometry according to 
the methodology described by Brant et al. [22].
Parasitaemia, clinical signs and liver function
Mice were observed daily for parasitaemia, survival and 
clinical signs of CM (i.e. ataxia, paralysis, and coma). CM 
signs were evaluated using the rapid murine coma and 
behaviour scale (RMCBS), a protocol based on the com-
ponents of the SHIRPA (SmithKline/Harwell/Imperial 
College/Royal Hospital/Phenotype Assessment) score 
[36]. The RMCBS consists of ten parameters (gait, bal-
ance, motor performance, body position, limb strength, 
touch scape, pinna reflex, toe pinch, aggression and 
grooming), and each item is scored from zero as the low-
est, to two as the highest, with a maximum total score of 
20. This scale is a quantitative and objective method that 
enables a rapid follow up of CM course. This assessment 
was carried out daily from day 3 dpi until day 7 dpi. For 
haematocrit determination at 5 dpi, blood samples were 
collected into heparinized capillary tubes, and centri-
fuged for 10  min in a haematocrit centrifuge (HT, São 
Paulo, Brazil). Liver function of P. berghei-infected and 
control mice was determined by measuring the levels 
of alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) in serum at 5 dpi using a commer-
cially available kit following the manufacturer’s protocol 
(Quibasa, Bioclin, Belo Horizonte, Brazil).
Brain pathology and quantification of cytokines
At 5  dpi mice were euthanized with ketamine/xylazine, 
the brain was carefully removed, immediately fixed in 
4  % buffered formalin and tissue fragment was embed-
ded in paraffin. Tissue sections (4 µm thick) were stained 
with haematoxylin and eosin (H&E) and examined under 
light microscopy. Sections were captured with a digital 
camera (DEI-470; Optronics, Goleta, CA, USA) con-
nected to a microscope (IX70; Olympus, Center Valley, 
PA, USA) with a magnification of 20×. For quantifica-
tion of cytokines, brains and spleens were homogenized 
in a PBS-buffer containing a protease-inhibitor cocktail 
to determine the concentrations of the cytokines IFN-
γ, TNF, IL-1β, IL-6, IL-10, IL-12, IL-17 and TGF-β by 
enzyme-linked immunosorbent assay (ELISA) DuoSet 
kits (R&D Systems, Minneapolis, MN, USA), in accord-
ance to the manufacturer’s instructions.
Treatment of infected red blood cells in vitro
Parasitized blood was collected from P. berghei-infected 
mice displaying a 5–8  % parasitaemia and was pre-
treated with a concentration of 500 μg/mL of A. blazei 
aqueous extract, lyophilized extract or fraction C. After 
1  h of incubation, untreated infected red blood cells or 
A. blazei-treated infected red blood cells were cen-
trifuged (Centrifuge 5415R, Eppendorf ) in 100×g for 
5 min at 24 °C. The supernatant was discarded and PBS 
was added, followed by intraperitoneal inoculation in 
C57BL/6 mice.
Statistical analysis
Data was analysed by statistical and Graph Prism Soft-
ware 4.0 (GraphPad, La Jolla, CA, USA). Results are 
shown as mean ± standard error of the mean (SEM). Dif-
ferences were compared by using two-tailed Student’s t 
tests with 95 % confidence intervals, analysis of variance 
(ANOVA) or Two-way ANOVA followed by Bonferroni’s 
corrections as needed for multiple comparisons when 
parametric assumptions were met. Differences between 
lethality curves were calculated using Log rank test. 
Results with a P < 0.05 were considered significant.
Results
Characterization of the Agaricus blazei crude extract
The chemical characteristics of the A. blazei crude 
extract were investigated. Figure 1 demonstrates that the 
A. blazei crude extract is rich in carbohydrates, proteins 
and, to a lesser extent, phenolic compounds (Fig.  1a). 
The protein profile ranged from 45 to 25  kDa (Fig.  1b) 
and its concentration was also used as a reference for the 
analyses of the anti-malarial activity (based on previous 
studies of the microbicidal activity of A. blazei against 
Leishmania infection [18–20]. Figure 1c, shows that this 
extract has elevated antioxidant capacity.
Administration of Agaricus blazei aqueous extract 
decreases parasitaemia and increases survival 
of Plasmodium berghei‑infected mice
Agaricus blazei aqueous extract-treated mice (100  mg/
Kg) displayed a significant decline in parasitaemia when 
compared with untreated mice at 6 and 7  dpi (Fig.  2a). 
There was increased survival (~85  %) for an addi-
tional 20 days (Fig. 2b), and no clinical signs were noted 
(Fig.  2c). Untreated P. berghei-infected mice (~90  %) 
developed ataxia, loss of grip strength, progressive 
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paralysis, coma, ruffled fur and significant weight loss 
(Fig.  2c, d) between 6 and 7  dpi. A. blazei aqueous 
extract-treated mice had non-significant reduction in 
body weight (Fig. 2d). None of the groups showed signifi-
cant differences in haematocrit at 5 dpi (Fig. 2e). When 
A. blazei aqueous extract was administrated to infected 
mice at dose of 10  mg/kg the course of infection was 
comparable with untreated infected mice (see Addi-
tional file 1A-C) indicating, that in low concentration this 
extract is not effective. Next, was then tested whether 
the A. blazei extract in lyophilized form could exert anti-
malarial activity since lyophilized formulations increase 
storage time and the product quality [37]. Administration 
of 80 mg/kg of A. blazei lyophilized extract did not con-
fer resistance against P. berghei-infection (see Additional 
file 2A, B). However, administration of 800 mg/kg of A. 
blazei lyophilized extract to infected mice resulted in 
significant survival (~80  %) and no visible clinical sings 
of CM (see Additional file  2A, B). Transaminase deter-
minations revealed no hepatic cytotoxic effects dur-
ing A. blazei administration (see Additional file  3A, B). 
The mushroom extract has very low toxicity in animal 
models [38, 39] and is likely safe for human at concentra-
tions from 900 to 1,500 mg/day for until 1 year of treat-
ment [40–42]. Mice treated with chloroquine displayed a 
decline in parasitaemia and increased survival (Fig. 2).
Administration of purified Agaricus blazei fraction protects 
against Plasmodium berghei infection
Next was determined whether there was a specific A. 
blazei purified fraction responsible for the observed 
anti-malarial activity. It was found fractions A, B and 
C, which were characterized by chemical composition, 
protein profile and antioxidant activity (Fig. 3a–c), were 
separated by differences in MW. Fraction A had a MW 
greater than 10 kDa, the MW of fraction B was between 
3 and 10 kDa, and fraction C had a MW less than 3 kDa. 
All three fractions had large amounts of carbohydrate 
(73.37 % for fraction A, 55.37 % for fraction B and 56.86 % 
for fraction C). Fractions B and C contained higher levels 
of protein (38.11 and 37.37 %, respectively) and phenolic 
compounds (4.73 and 4.96 %, respectively) than fraction 
A (22.39  % protein and 2.12  % phenolic compounds). 
Fraction C contained the lowest percentage of flavonoids 
(0.81 %) (Fig. 3a). The protein profile demonstrated sev-
eral proteins with different MWs. However, both frac-
tions B and C had proteins with MWs less than 14.4 kDa 
(Fig. 3b). The high protein content of the fractions B and 
C is likely due to the presence of peptides (Fig. 3b). There 
were higher antioxidant activities in fractions B and C, 
and lower activity in fraction A (Fig. 3c).
The anti-malarial activity of these three fractions was 
also evaluated. There were no significant differences in 
parasitaemia and mortality between those mice treated 
with fraction A (10  mg/kg) and untreated infected 
mice (see Additional file  4A-C), and this fraction was 
no longer studied. The fraction B was administered at 
doses of 10, 80 and 800 mg/kg (see Additional file 5). It 
was observed that different doses of fraction B were not 
effective in controlling parasite replication, and treated 
mice died between 6 and 10  dpi, similar to untreated 
infected mice (see Additional file 5A, B). Next, the anti-
malarial activity of fraction C was examined using a dose 
of 100  mg/kg (Fig.  3d), the same used for the aqueous 
extract. Mice treated with fraction C did not show sig-
nificant differences in parasitaemia during the first 7 dpi, 
contrasting the results observed with aqueous A. blazei 
treatment. Despite this, fraction C-treated-mice survived 
more than 15  dpi (~80  %) (Fig.  3e) and did not display 
clinical signs (see Additional file 6A) of CM when com-
pared to untreated infected mice. Similarly to untreated 
infected group, fraction C-treated-mice displayed signifi-
cant weight loss (Fig. 3f ). There were no significant differ-
ences in haematocrit between the groups (see Additional 
file 6B).
Fig. 1 Characterization of the crude extract of Agaricus blazei. a Par-
tial chemical composition of the crude extract of A. blazei. b Analysis 
by SDS-Page 12 % polyacrylamide of the crude extract of A. blazei. 
c Measurement of antioxidant activity of the crude extract from the 
absorbance of DPPH free radical, the decrease in absorbance repre-
sents stabilization of this free radical. MM molecular mass markers, CE 
crude extract of A. blazei.
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Administration of Agaricus blazei results in modulation 
of immune response and protection against brain damage 
during Plasmodium berghei infection
Infection-associated induction of pro-inflammatory 
cytokines such as IFN-γ, TNF and IL-1β poses a dou-
ble-edged sword. Cytokines are essential for control of 
parasite growth but are also associated with tissue dam-
age both in experimental and clinical settings. In the 
spleen, the levels of TNF and IL-1β did not change as a 
result of the administration of the extract. IL-12 produc-
tion was significantly decreased in mice receiving aque-
ous extract when compared with untreated infected mice 
Fig. 2 Administration of aqueous extract results in the resistance of mice to Plasmodium berghei-infection. C57BL/6 mice received 100 mg/kg of 
A. blazei extract or chloroquine (30 mg/kg) 3 days before infection, then infected with 105 P. berghei red blood cells (pRBCs), and treated until 7 dpi. 
a Parasitaemia, b survival and c clinical signs of cerebral malaria assessed by the RMCBS scale and d body weight of untreated P. berghei-infected 
mice and treated with chloroquine or A. blazei aqueous extract. Neurologic signs of CM appeared on days 6–12 (shaded area), with death occurring 
24–48 h after onset. e Haematocrit was assessed on 5th dpi in the above groups and in mice uninfected. Parasitaemia, body weight and haemato-
crit (%) values are expressed as mean ± SD of 5 mice per group. #p < 0.001, log-rank test and **p < 0.01 and ***p < 0.001, ANOVA followed Bonfer-
roni’s test.
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(Fig. 4a). Infected mice that received the aqueous extract 
or fraction C displayed a significant reduction of IL-6, 
IL-10, IL-17, IFN-γ and TGF-β levels when compared 
with untreated infected mice. Similar results were also 
observed in infected mice that received the chloroquine 
demonstrating reduced levels of those cytokines, except 
for IL-6 and TGF-β when compared to untreated-
infected mice (Fig. 4a).
There was a significant reduction of TNF, IL-1β and 
IL-6 levels in the brains of infected mice that received 
Fig. 3 Administration of fraction C of Agaricus blazei protects mice against P. berghei infection. a Characterization of fractions of the crude extract of 
A. blazei with the partial chemical composition of fractions A–C (in percentage), b analysis by SDS-Page 12 % polyacrylamide of fractions obtained 
from the purification of the crude extract and c measurement of antioxidant activity of fractions of AbM. MM molecular mass markers, CE Crude 
Extract, FA Fraction A; FB Fraction B; FC Fraction C. C57BL/6 mice received 100 mg/kg of A. blazei Fraction C or chloroquine (30 mg/kg) 3 days 
before infection, then infected with 105 parasitized RBCs IP via, and treated until 7th day post infection. d Parasitaemia, survival and body weight in 
untreated P. berghei-infected mice and treated with chloroquine or fraction C. Neurologic signs of CM appeared on days 6–12 (shaded area), with 
death occurring 24–48 h after onset. Parasitaemia and body weight values are expressed as mean ± SD of 5 mice per group. #p < 0.001, log-rank 
test; ANOVA followed Bonferroni’s test.
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the A. blazei when compared to untreated-infected 
mice. There were no significant differences in IL-10, 
IL-12, IL-17, IFN-γ and TGF-β levels among the groups 
treated with A. blazei compared with untreated-infected 
mice (Fig.  4b). Increased levels of IL-12, IL-17, IFN-γ 
and TGF-β were observed in the brain of infected chlo-
roquine-treated mice when compared with untreated 
infected mice. Taken together, these data suggest that A. 
blazei modulates cytokine production in the spleen and 
brain of infected mice (Fig. 4a, b).
Next, was examined whether A. blazei aqueous extract 
or fraction C protected the brain of P. berghei-infected 
mice. Histological examination of brains from infected at 
5  dpi revealed necrosis and hemorrhage in the cerebral 
cortex of untreated infected mice in contrast to A. blazei-
treated infected mice. In chloroquine-treated mice there 
were areas of discrete hemorrhage (Fig. 4c).
Anti‑parasitic effect of Agaricus blazei in Plasmodium 
berghei
To evaluate the direct effect of A. blazei on the para-
site, P. berghei-infected red blood cells (RBCs) were pre-
treated with A. blazei aqueous extract or fraction C for 
1  h in  vitro, and then was injected (i.p.) these treated 
RBCs into C57BL/6 mice. Mice injected with untreated-
parasitized RBCs developed CM associated with ataxia, 
loss of grip strength, progressive paralysis, and coma suc-
cumbing between 8 and 11 dpi (~80 %)(Fig. 5). However, 
mice receiving P. berghei-infected RBCs treated with A. 
blazei aqueous extract or fraction C displayed signifi-
cantly parasitaemia reduction, no neurological dysfunc-
tion and significant increased survival (Fig.  5a, b). All 
groups displayed progressive decline in weight (Fig. 5c).
Discussion
The major findings of the current study can be summa-
rized as follows: (1) A. blazei crude aqueous extract is 
effective in  vitro and in  vivo against P. berghei; (2) the 
activity resides mainly in a fraction of low MW com-
pounds, denominated fraction C; (3) fraction C delays 
lethality and protects from tissue damage. Indeed, 
fraction C is more effective than chloroquine in protect-
ing against cerebral damage caused by the parasite; (4) 
incubation of the parasite with fraction C prior to infec-
tion causes partial protection from disease, suggesting 
the compound has direct effects on the parasite. Alto-
gether, these findings suggest that molecules derived 
from A. blazei may be useful for the treatment of cerebral 
malaria.
Herein, it was reported that the administration of A. 
blazei extract to mice infected with P. berghei improved 
the development of CM. Both A. blazei aqueous extract 
and purified fraction C have antioxidant activity, which 
may be responsible for their anti-parasitic and immu-
nomodulatory effects. It has been demonstrated that A. 
blazei decreased lipid peroxidation in aged rats, demon-
strating the capacity of the mixture to possess antioxi-
dant effects in vivo [43]. A. blazei fraction C is a mixture 
of low MW compounds, including phenolic compounds, 
carbohydrates and peptides (Fig. 3). Other studies dem-
onstrated that phenolic compounds and peptides may 
have immunomodulatory and/or anti-parasitic activity 
[13, 44]. It was demonstrated that chemical analysis of A. 
blazei by phytochemical screening indicated the presence 
of glycoproteins, carbohydrates and tannins [20]. There 
were three phenolic compounds in A. blazei—gallic acid, 
syringic acid, and pyrogallol. These compounds possess 
pronounced antioxidant activity [45]. Additional studies 
will be required to elucidate the precise molecular com-
position of fraction C that is responsible for anti-parasitic 
and immunomodulatory activity and whether the anti-
oxidant activity does indeed contribute to the protection 
observed in vivo.
Oxidative stress has been linked to neurological and 
cognitive impairment in CM [46]. In the present study, 
we demonstrated that administration of A. blazei aque-
ous extract or fraction C protected the brain from the 
damaging effects of this infection. In this regard, previous 
studies indicated that one activity of this mushroom is 
related with ROS scavenging and inhibition of lipid per-
oxidation [4, 12, 47], which may be attributed, at least in 
part, to the phenolic compounds identified in A. blazei 
(See figure on previous page.)
Fig. 4 Administration of Agaricus blazei modulated cytokine expression in the spleen and brain and protected against CM development. C57BL/6 
mice were pre-treated with 100 mg/kg of A. blazei extract, Fraction C (100 or 800 mg/kg) or chloroquine (30 mg/kg) 3 days before infection, then 
infected with 105 parasitized RBCs IP via, and treated until 5 dpi. Production of IL-12, IFN-γ, TNF, IL-6, IL-1β, IL-17, IL-10 and TGF-β in the spleen (a) and 
in the brain (b) in response to infection with P. berghei, measured at 5 dpi. Cytokines expression was normalized relative to that of uninfected controls 
for each mouse group. c Representative histological (H&E) stained of cerebral cortex of mice, demonstrating severity of cerebral pathology on 5 dpi. 
It is observed cerebral cortex with normal histological aspect, containing healthy neurons in mice-uninfected and with extensive hemorrhagic 
area (arrow), surrounded by hyperchromatic and condensed neurons (asterisks) in P. berghei-infected animal. Small haemorrhagic focus (arrow) was 
detected in the brain of mice treated with chloroquine and cerebral parenchyma with normal histological aspect in mice treated with AbM aqueous 
extract or fraction C. Original magnification ×20. Values are expressed as mean ± SD of 5 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 
compared to P. berghei-infected mice, ANOVA followed Bonferroni’s test.
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[20]. Additionally, previous studies have demonstrated 
that A. blazei treatment was successful in improving the 
oxidative state of the brain of old rats and was capable of 
decrease levels of lipid peroxidation (TBARS) of old rats 
[43]. These results suggest that treatment with A. blazei 
can provide antioxidant activity to the brain in vivo.
It has been reported that antioxidants act by reducing 
ROS activity and inhibiting lipid peroxidation induced 
by Plasmodium in membrane of parasitized erythro-
cytes [48], suggesting that the observed anti-malarial 
effect may be related to the antioxidant activity of frac-
tion C. This effect could be, in part, the result of iron 
chelation [3]. Anti-malarial drugs such as chloroquine, 
amodiaquine, primaquine and artemisinin are thought 
to kill the parasite by the induction of oxidative stress 
to eliminate the parasite [49]. However, this may also 
lead to ROS-induced damage to the host [49] as well as 
drug resistance [50, 51]. In fact, chloroquine treatment, 
although effective in preventing mortality and reducing 
parasitaemia, did not prevent protection against brain 
damage [46, 52]. Therefore, the antioxidant activity of 
fraction C may be important for the control of CM devel-
opment in the experimental model of severe malaria.
In fact, the present study demonstrates that the admin-
istration of fraction C did not completely eliminate para-
sitaemia and weight loss despite significantly increasing 
survival of mice and protecting the brain. This is in agree-
ment with studies by Ibrahim et  al. [48] that using the 
antioxidant also failed to control the parasitaemia in mice 
infected with P. berghei. It is important to note that the 
elimination of parasitaemia is not always associated with 
improvement in clinical outcome either in humans or in 
animal models [29, 53, 54]. Similarly, while the increased 
production of cytokines in the early infection is impor-
tant for parasite control it likely contributes to brain 
damage and cognitive dysfunction associated with CM.
Our results indicate that the administration of A. 
blazei in P. berghei-infected mice modified the profile of 
cytokines produced in the spleen compared to P. berghei-
infected or chloroquine-treated-infected mice. There was 
a reduction in the expression of TNF, IL-1β and IL-6 in 
the brain of A. blazei aqueous extract-treated mice and 
of TNF in A. blazei fraction C-treated mice. The induc-
tion of these cytokines is associated with the expression 
of cell adhesion molecules, synthesis of other proinflam-
matory cytokines, apoptosis and activated phagocytes, all 
of which have been described in CM [53, 55, 56]. Stud-
ies by Lyke et  al. [57] and Wunderlich et  al. [58], dem-
onstrated that high IL-6 levels were detected in children 
and mice that developed severe CM. Thus, the reduction 
levels of TNF, IL-1β and IL-6 levels in A. blazei-treated 
mice could be related to brain protection and increase in 
survival (Figs. 4b, c, 2b, 3e), observed in the study.
Treatment with chloroquine resulted in an increased 
production of most proinflammatory cytokines in 
the brain (IL-12, IFN-γ and IL-17) when compared to 
untreated-infected and A. blazei-treated infected mice. 
The elevation of TGF-β in chloroquine-treated-infected 
mice may be associated with two possibilities: (1) inhibit/
diminish the proinflammatory response or (2) could be 
involved with the brain damage. These alterations (eleva-
tion of IL-12, IFN-γ, IL-17 and TGF-β) could explain, in 
part, the histopathologic changes observed in chloro-
quine-treated mice (Fig. 4c). In agreement, it have been 
previously reported in clinical and experimental stud-
ies a role for TGF-β in malaria severity [59–61]. Taken 
together, our findings indicate a potential deleterious 
effect of chloroquine in the CNS not observed with A. 
blazei treatment. Other studies have shown that chloro-
quine was highly effective in decreasing parasitaemia and 
preventing mortality, but failed to prevent cognitive and 
behavioral functions altered in mice subjected to CM. 
Fig. 5 Anti-parasitic effects of extract or fraction C of Agaricus blazei. a Parasitaemia, b survival and c body weight of mice infected with untreated 
pRBCs or treated during 1 h with A. blazei water extract or fraction C (500 μg/mL) in vitro. Neurologic signs of CM appeared on days 6–12 (shaded 
area), with death occurring 24–48 h after onset. Parasitaemia and body weight values are expressed as mean ± SD of 4 mice per group. #p < 0.001, 
log-rank test and *p < 0.05, ANOVA followed Bonferroni’s test.
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These studies suggest that anti-malarial treatment is not 
sufficient to protect against the consequences of CM and 
limiting the inflammatory damage in the brain is neces-
sary in addition to anti-malarials to improve CM out-
come [46, 52, 62].
The injection of P. berghei-infected RBCs pre-incubated 
with A. blazei aqueous extract or fraction C, was effec-
tive in preventing CM. Although this incubation period 
was brief, it was effective and similar to previous findings 
with Leishmania species [18–20]. This result indicated 
a direct effect of A. blazei on parasite suggesting that it 
could contribute to control of parasite replication.
Conclusion
Treatment with the mushroom A. blazei is effective in 
preventing the development of experimental CM and 
may represent an alternative therapy in the treatment of 
malaria. Additional studies are needed to identification of 
compounds isolated from A. blazei fraction C responsi-
ble for the anti-malarial activity and establish its molec-
ular mechanism of action. Moreover, the efficacy of the 
combination with other known anti-malarial drugs, and 
their long-term effect on outcome remains to be fully 
addressed. These studies may lead to novel therapeutic 
approaches both in the chemoprophylaxis and treatment 
of malaria.
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Additional files
Additional file 1. Administration of Agaricus blazei aqueous extract 
at dose of 10 mg/kg did not confer protection during P. berghei ANKA 
infection. C57BL/6 mice received 10 mg/kg of A. blazei aqueous extract 
or chloroquine (30 mg/kg) three days before infection, then infected with 
105 pRBCs, and treated until 7 dpi. (A) Parasitaemia, (B) survival and (C) 
body weight loss of control P. berghei-infected mice and administered 
with chloroquine or aqueous extract of the A. blazei. Parasitaemia and 
body weight values are expressed as mean ± SD of 5 mice per group. 
Log-rank test and ***p < 0.001, ANOVA followed Bonferroni’s test.
Additional file 2. Administration of 800 mg/kg of Agaricus blazei lyo-
philized extract resulted in significant survival of P. berghei ANKA-infected 
mice. (A) Parasitaemia and (B) survival of C57BL/6 mice that received 
80 mg/kg or 800 mg/kg of A. blazei lyophilized extract or 30 mg/kg of 
chloroquine three days before infection, then infected with 105 pRBCs, 
and treated until 7 dpi. Parasitaemia expressed as mean ± SD of 5 mice 
per group. (A) ANOVA followed Bonferroni’s test was applied and (B) 
#p<0.001 Log-rank test.
Additional file 3. Transaminase determinations revealed no hepatic 
cytotoxic effects during A. blazei administration. C57BL/6 mice received 
100 mg/kg of A. blazei extract, 100 mg/kg or 800 mg/kg of fraction C or 
30 mg/kg of chloroquine three days before infection, then infected with 
105 parasitized RBCs IP via, and treated until 5 dpi. Transaminase deter-
minations, (A) AST and (B) ALT were performed at 5 dpi in serum. Values 
are expressed as mean ± SD of 5 mice per group and ANOVA followed 
Bonferroni’s test was applied.
Additional file 4. There were no differences in parasitaemia and mortal-
ity between those mice treated with fraction A and untreated mice during 
P. berghei ANKA infection. (A) Parasitaemia, (B) survival and (C) body 
weight loss of C57BL/6 mice that received 10 mg/kg of A. blazei fraction 
A or 30 mg/kg of chloroquine three days before infection, then infected 
with 105 pRBCs, and treated until 7 dpi. Parasitaemia and body weight 
values are expressed as mean ± SD of 5 mice per group. Log-rank test and 
*p < 0.05, **p < 0.01 and ***p < 0.001, ANOVA followed Bonferroni’s test.
Additional file 5. Different doses of fraction B were not effective in 
controlling the P. berghei ANKA infection. (A) Parasitaemia, (B) survival and 
(C) body weight loss of control P. berghei-infected mice and administered 
chloroquine or fraction B (10, 80 and 800 mg/kg). C57BL/6 mice were 
treated with A. blazei or chloroquine three days before infection, then 
infected with 105 pRBCs, and treated until 7 dpi. Parasitaemia and body 
weight values are expressed as mean ± SD of 5 mice per group. Log-rank 
test and *p < 0.05, **p < 0.01 and ***p < 0.001, ANOVA followed Bonfer-
roni’s test.
Additional file 6. Fraction C treated mice did not display clinical signs of 
CM and significant differences in haematrocrit during P. berghei infection. 
C57BL/6 mice were treated with fraction C of A. blazei or chloroquine 
three days before infection, then infected with 105 pRBCs, and treated 
until 7 dpi. (A) clinical signs of cerebral malaria assessed by the RMCBS 
score and (B) haematocrit assessed on 5th dpi, normalized relative to 
that of uninfected controls for each mouse group. RMCBS score and 
haematocrit values were expressed as mean ± SD of 5 mice per group. 
***p < 0.001, ANOVA followed Bonferroni’s test.
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